---
document_datetime: 2025-12-21 07:01:27
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/kesimpta.html
document_name: kesimpta.html
version: success
processing_time: 0.1080735
conversion_datetime: 2025-12-25 05:08:13.121975
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Kesimpta

[RSS](/en/individual-human-medicine.xml/67426)

##### Authorised

This medicine is authorised for use in the European Union

ofatumumab Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Kesimpta](#news-on)
- [More information on Kesimpta](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Kesimpta is a medicine for treating adults with relapsing forms of multiple sclerosis (MS), where the patient has flare-ups (relapses) followed by periods with milder or no symptoms. It is used in patients with active disease, which means that they have relapses and/or signs of active inflammation on scans.

Kesimpta contains the active substance ofatumumab.

Expand section

Collapse section

## How is Kesimpta used?

Kesimpta can only be obtained with a prescription and treatment should be started by a doctor experienced in the management of conditions of the nervous system.

Kesimpta is available as a solution for injection in prefilled syringes or prefilled pens. Treatment starts with one injection under the skin every week for 3 weeks, followed by a week with no injection. The next injection is given a week later and then an injection is given every month. Patients can inject themselves with Kesimpta once they have been trained.

For more information about using Kesimpta, see the package leaflet or contact your doctor or pharmacist.

## How does Kesimpta work?

The active substance in Kesimpta, ofatumumab, is a monoclonal antibody (a type of protein) that has been designed to recognise and attach to a specific target called CD20 on the surface of B cells (a type of white blood cell).

B cells play a key role in multiple sclerosis by attacking the protective covering (sheaths) around the nerves in the brain and spinal cord, causing inflammation and damage. By targeting B cells, Kesimpta helps to reduce their activity and thereby relieves symptoms or slows down the worsening of the disease.

## What benefits of Kesimpta have been shown in studies?

Studies have shown that Kesimpta is effective at reducing the number of relapses and can also delay the worsening of symptoms.

In two main studies of 1,882 patients with relapsing forms of multiple sclerosis, the average number of relapses in a year in patients treated with Kesimpta was less than half that in patients treated with another multiple sclerosis medicine, teriflunomide (0.11 versus 0.24 relapses per year). The studies also showed that fewer patients taking Kesimpta (8%) had worsening symptoms lasting 6 months or more compared with those taking teriflunomide (12%).

## What are the risks associated with Kesimpta?

The most common side effects with Kesimpta (which may affect more than 1 in 10 people) are upper respiratory tract infections (nose and throat infections), urinary tract infections (infections of the structures that carry urine), reactions at the site of injection (redness, pain, itching, and swelling) and injection-related reactions (fever, headache, muscle pain, chills and tiredness).

For the full list of side effects of Kesimpta, see the package leaflet.

Kesimpta must not be used in patients with severe active infections, severely weakened immune systems or cancer.

For the full list of restrictions, see the package leaflet.

## Why is Kesimpta authorised in the EU?

Studies showed that Kesimpta was more effective than teriflunomide at reducing the number of relapses in patients with relapsing forms of multiple sclerosis. The medicine was also more effective at delaying the worsening of symptoms. Side effects are in line with those of other similar medicines and are considered manageable. The European Medicines Agency decided that Kesimpta's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Kesimpta?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Kesimpta have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of the medicine are continuously monitored. Side effects reported with the medicine are carefully evaluated and any necessary action taken to protect patients.

## Other information about Kesimpta

Kesimpta received a marketing authorisation valid throughout the EU on 26 March 2021.

Kesimpta : EPAR - Medicine overview

Reference Number: EMA/130764/2021

English (EN) (119.19 KB - PDF)

**First published:** 16/04/2021

[View](/en/documents/overview/kesimpta-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-31)

български (BG) (142.71 KB - PDF)

**First published:**

16/04/2021

[View](/bg/documents/overview/kesimpta-epar-medicine-overview_bg.pdf)

español (ES) (119.01 KB - PDF)

**First published:**

16/04/2021

[View](/es/documents/overview/kesimpta-epar-medicine-overview_es.pdf)

čeština (CS) (139.64 KB - PDF)

**First published:**

16/04/2021

[View](/cs/documents/overview/kesimpta-epar-medicine-overview_cs.pdf)

dansk (DA) (118.38 KB - PDF)

**First published:**

16/04/2021

[View](/da/documents/overview/kesimpta-epar-medicine-overview_da.pdf)

Deutsch (DE) (122.6 KB - PDF)

**First published:**

16/04/2021

[View](/de/documents/overview/kesimpta-epar-medicine-overview_de.pdf)

eesti keel (ET) (107.45 KB - PDF)

**First published:**

16/04/2021

[View](/et/documents/overview/kesimpta-epar-medicine-overview_et.pdf)

ελληνικά (EL) (142.66 KB - PDF)

**First published:**

16/04/2021

[View](/el/documents/overview/kesimpta-epar-medicine-overview_el.pdf)

français (FR) (120.2 KB - PDF)

**First published:**

16/04/2021

[View](/fr/documents/overview/kesimpta-epar-medicine-overview_fr.pdf)

hrvatski (HR) (138.88 KB - PDF)

**First published:**

16/04/2021

[View](/hr/documents/overview/kesimpta-epar-medicine-overview_hr.pdf)

italiano (IT) (117.57 KB - PDF)

**First published:**

16/04/2021

[View](/it/documents/overview/kesimpta-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (149.9 KB - PDF)

**First published:**

16/04/2021

[View](/lv/documents/overview/kesimpta-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (140.47 KB - PDF)

**First published:**

16/04/2021

[View](/lt/documents/overview/kesimpta-epar-medicine-overview_lt.pdf)

magyar (HU) (142.87 KB - PDF)

**First published:**

16/04/2021

[View](/hu/documents/overview/kesimpta-epar-medicine-overview_hu.pdf)

Malti (MT) (142.5 KB - PDF)

**First published:**

16/04/2021

[View](/mt/documents/overview/kesimpta-epar-medicine-overview_mt.pdf)

Nederlands (NL) (118.2 KB - PDF)

**First published:**

16/04/2021

[View](/nl/documents/overview/kesimpta-epar-medicine-overview_nl.pdf)

polski (PL) (143.91 KB - PDF)

**First published:**

16/04/2021

[View](/pl/documents/overview/kesimpta-epar-medicine-overview_pl.pdf)

português (PT) (120.53 KB - PDF)

**First published:**

16/04/2021

[View](/pt/documents/overview/kesimpta-epar-medicine-overview_pt.pdf)

română (RO) (138.85 KB - PDF)

**First published:**

16/04/2021

[View](/ro/documents/overview/kesimpta-epar-medicine-overview_ro.pdf)

slovenčina (SK) (141.46 KB - PDF)

**First published:**

16/04/2021

[View](/sk/documents/overview/kesimpta-epar-medicine-overview_sk.pdf)

slovenščina (SL) (136.16 KB - PDF)

**First published:**

16/04/2021

[View](/sl/documents/overview/kesimpta-epar-medicine-overview_sl.pdf)

Suomi (FI) (116.89 KB - PDF)

**First published:**

16/04/2021

[View](/fi/documents/overview/kesimpta-epar-medicine-overview_fi.pdf)

svenska (SV) (117.49 KB - PDF)

**First published:**

16/04/2021

[View](/sv/documents/overview/kesimpta-epar-medicine-overview_sv.pdf)

Kesimpta : EPAR - Risk-management-plan summary

English (EN) (69.99 KB - PDF)

**First published:** 16/04/2021

**Last updated:** 29/03/2023

[View](/en/documents/rmp-summary/kesimpta-epar-risk-management-plan-summary_en.pdf)

## Product information

Kesimpta : EPAR - Product information

English (EN) (848.63 KB - PDF)

**First published:** 16/04/2021

**Last updated:** 16/12/2025

[View](/en/documents/product-information/kesimpta-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-72)

български (BG) (934.53 KB - PDF)

**First published:**

16/04/2021

**Last updated:**

16/12/2025

[View](/bg/documents/product-information/kesimpta-epar-product-information_bg.pdf)

español (ES) (933.79 KB - PDF)

**First published:**

16/04/2021

**Last updated:**

16/12/2025

[View](/es/documents/product-information/kesimpta-epar-product-information_es.pdf)

čeština (CS) (949.79 KB - PDF)

**First published:**

16/04/2021

**Last updated:**

16/12/2025

[View](/cs/documents/product-information/kesimpta-epar-product-information_cs.pdf)

dansk (DA) (906.95 KB - PDF)

**First published:**

16/04/2021

**Last updated:**

16/12/2025

[View](/da/documents/product-information/kesimpta-epar-product-information_da.pdf)

Deutsch (DE) (955.11 KB - PDF)

**First published:**

16/04/2021

**Last updated:**

16/12/2025

[View](/de/documents/product-information/kesimpta-epar-product-information_de.pdf)

eesti keel (ET) (921.38 KB - PDF)

**First published:**

16/04/2021

**Last updated:**

16/12/2025

[View](/et/documents/product-information/kesimpta-epar-product-information_et.pdf)

ελληνικά (EL) (1021.74 KB - PDF)

**First published:**

16/04/2021

**Last updated:**

16/12/2025

[View](/el/documents/product-information/kesimpta-epar-product-information_el.pdf)

français (FR) (993.51 KB - PDF)

**First published:**

16/04/2021

**Last updated:**

16/12/2025

[View](/fr/documents/product-information/kesimpta-epar-product-information_fr.pdf)

hrvatski (HR) (936.43 KB - PDF)

**First published:**

16/04/2021

**Last updated:**

16/12/2025

[View](/hr/documents/product-information/kesimpta-epar-product-information_hr.pdf)

íslenska (IS) (943.62 KB - PDF)

**First published:**

16/04/2021

**Last updated:**

16/12/2025

[View](/is/documents/product-information/kesimpta-epar-product-information_is.pdf)

italiano (IT) (946.46 KB - PDF)

**First published:**

16/04/2021

**Last updated:**

16/12/2025

[View](/it/documents/product-information/kesimpta-epar-product-information_it.pdf)

latviešu valoda (LV) (902.4 KB - PDF)

**First published:**

16/04/2021

**Last updated:**

16/12/2025

[View](/lv/documents/product-information/kesimpta-epar-product-information_lv.pdf)

lietuvių kalba (LT) (994.79 KB - PDF)

**First published:**

16/04/2021

**Last updated:**

16/12/2025

[View](/lt/documents/product-information/kesimpta-epar-product-information_lt.pdf)

magyar (HU) (1017.16 KB - PDF)

**First published:**

16/04/2021

**Last updated:**

16/12/2025

[View](/hu/documents/product-information/kesimpta-epar-product-information_hu.pdf)

Malti (MT) (1.02 MB - PDF)

**First published:**

16/04/2021

**Last updated:**

16/12/2025

[View](/mt/documents/product-information/kesimpta-epar-product-information_mt.pdf)

Nederlands (NL) (973.63 KB - PDF)

**First published:**

16/04/2021

**Last updated:**

16/12/2025

[View](/nl/documents/product-information/kesimpta-epar-product-information_nl.pdf)

norsk (NO) (901.73 KB - PDF)

**First published:**

16/04/2021

**Last updated:**

16/12/2025

[View](/no/documents/product-information/kesimpta-epar-product-information_no.pdf)

polski (PL) (948.79 KB - PDF)

**First published:**

16/04/2021

**Last updated:**

16/12/2025

[View](/pl/documents/product-information/kesimpta-epar-product-information_pl.pdf)

português (PT) (983.97 KB - PDF)

**First published:**

16/04/2021

**Last updated:**

16/12/2025

[View](/pt/documents/product-information/kesimpta-epar-product-information_pt.pdf)

română (RO) (970.92 KB - PDF)

**First published:**

16/04/2021

**Last updated:**

16/12/2025

[View](/ro/documents/product-information/kesimpta-epar-product-information_ro.pdf)

slovenčina (SK) (962.94 KB - PDF)

**First published:**

16/04/2021

**Last updated:**

16/12/2025

[View](/sk/documents/product-information/kesimpta-epar-product-information_sk.pdf)

slovenščina (SL) (978.59 KB - PDF)

**First published:**

16/04/2021

**Last updated:**

16/12/2025

[View](/sl/documents/product-information/kesimpta-epar-product-information_sl.pdf)

Suomi (FI) (907.1 KB - PDF)

**First published:**

16/04/2021

**Last updated:**

16/12/2025

[View](/fi/documents/product-information/kesimpta-epar-product-information_fi.pdf)

svenska (SV) (907.41 KB - PDF)

**First published:**

16/04/2021

**Last updated:**

16/12/2025

[View](/sv/documents/product-information/kesimpta-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000317802 16/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Kesimpta : EPAR - All authorised presentations

English (EN) (93.16 KB - PDF)

**First published:** 16/04/2021

[View](/en/documents/all-authorised-presentations/kesimpta-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-312)

български (BG) (98.32 KB - PDF)

**First published:**

16/04/2021

[View](/bg/documents/all-authorised-presentations/kesimpta-epar-all-authorised-presentations_bg.pdf)

español (ES) (92.88 KB - PDF)

**First published:**

16/04/2021

[View](/es/documents/all-authorised-presentations/kesimpta-epar-all-authorised-presentations_es.pdf)

čeština (CS) (98.08 KB - PDF)

**First published:**

16/04/2021

[View](/cs/documents/all-authorised-presentations/kesimpta-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (96.16 KB - PDF)

**First published:**

16/04/2021

[View](/da/documents/all-authorised-presentations/kesimpta-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (95.56 KB - PDF)

**First published:**

16/04/2021

[View](/de/documents/all-authorised-presentations/kesimpta-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (89.74 KB - PDF)

**First published:**

16/04/2021

[View](/et/documents/all-authorised-presentations/kesimpta-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (97.82 KB - PDF)

**First published:**

16/04/2021

[View](/el/documents/all-authorised-presentations/kesimpta-epar-all-authorised-presentations_el.pdf)

français (FR) (90.48 KB - PDF)

**First published:**

16/04/2021

[View](/fr/documents/all-authorised-presentations/kesimpta-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (91.53 KB - PDF)

**First published:**

16/04/2021

[View](/hr/documents/all-authorised-presentations/kesimpta-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (95.06 KB - PDF)

**First published:**

16/04/2021

[View](/is/documents/all-authorised-presentations/kesimpta-epar-all-authorised-presentations_is.pdf)

italiano (IT) (92.84 KB - PDF)

**First published:**

16/04/2021

[View](/it/documents/all-authorised-presentations/kesimpta-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (96.68 KB - PDF)

**First published:**

16/04/2021

[View](/lv/documents/all-authorised-presentations/kesimpta-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (96.16 KB - PDF)

**First published:**

16/04/2021

[View](/lt/documents/all-authorised-presentations/kesimpta-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (98.38 KB - PDF)

**First published:**

16/04/2021

[View](/hu/documents/all-authorised-presentations/kesimpta-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (96.58 KB - PDF)

**First published:**

16/04/2021

[View](/mt/documents/all-authorised-presentations/kesimpta-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (91.63 KB - PDF)

**First published:**

16/04/2021

[View](/nl/documents/all-authorised-presentations/kesimpta-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (95.94 KB - PDF)

**First published:**

16/04/2021

[View](/no/documents/all-authorised-presentations/kesimpta-epar-all-authorised-presentations_no.pdf)

polski (PL) (98.91 KB - PDF)

**First published:**

16/04/2021

[View](/pl/documents/all-authorised-presentations/kesimpta-epar-all-authorised-presentations_pl.pdf)

português (PT) (91.06 KB - PDF)

**First published:**

16/04/2021

[View](/pt/documents/all-authorised-presentations/kesimpta-epar-all-authorised-presentations_pt.pdf)

română (RO) (95.72 KB - PDF)

**First published:**

16/04/2021

[View](/ro/documents/all-authorised-presentations/kesimpta-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (98.46 KB - PDF)

**First published:**

16/04/2021

[View](/sk/documents/all-authorised-presentations/kesimpta-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (92.57 KB - PDF)

**First published:**

16/04/2021

[View](/sl/documents/all-authorised-presentations/kesimpta-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (90.23 KB - PDF)

**First published:**

16/04/2021

[View](/fi/documents/all-authorised-presentations/kesimpta-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (93.63 KB - PDF)

**First published:**

16/04/2021

[View](/sv/documents/all-authorised-presentations/kesimpta-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Kesimpta Active substance ofatumumab International non-proprietary name (INN) or common name ofatumumab Therapeutic area (MeSH) Multiple Sclerosis, Relapsing-Remitting Anatomical therapeutic chemical (ATC) code L04AA52

### Pharmacotherapeutic group

Immunosuppressant

### Therapeutic indication

Kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features (see section 5.1).

## Authorisation details

EMA product number EMEA/H/C/005410

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Novartis Europharm Limited

Vista Building

Marketing authorisation issued 26/03/2021 Revision 13

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Kesimpta : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (145.25 KB - PDF)

**First published:** 16/12/2025

[View](/en/documents/procedural-steps-after/kesimpta-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Kesimpta : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (168.79 KB - PDF)

**First published:** 02/06/2021

**Last updated:** 16/12/2025

[View](/en/documents/procedural-steps-after/kesimpta-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Kesimpta-H-C-PSUSA-00010927-202309 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/328965/2024

English (EN) (164.68 KB - PDF)

**First published:** 12/07/2024

**Last updated:** 07/02/2025

[View](/en/documents/scientific-conclusion/kesimpta-h-c-psusa-00010927-202309-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Kesimpta : EPAR - Public assessment report

Adopted

Reference Number: EMA/160608/2021

English (EN) (6.16 MB - PDF)

**First published:** 16/04/2021

[View](/en/documents/assessment-report/kesimpta-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Kesimpta

Adopted

Reference Number: EMA/CHMP/17719/2021

English (EN) (134.48 KB - PDF)

**First published:** 01/02/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-kesimpta_en.pdf)

#### News on Kesimpta

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-29 January 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-29-january-2021) 29/01/2021

#### More information on Kesimpta

- [EMEA-002397-PIP01-18-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002397-pip01-18-m03)
- [Post-Authorization Safety Study for Assessment of Pregnancy and Infant Outcomes in Patients Treated with Kesimpta (ofatumumab) using OTIS Observational Pregnancy Surveillance Program and DMSKW Registry (Kesimpta Pregnancy Registry) - post-authorisation study](https://catalogues.ema.europa.eu/study/49804)
- [Evaluation of pregnancy and infant outcomes in Kesimpta patients using PRegnancy outcomes Intensive Monitoring (PRIM) data - The Kesimpta-PRIM study. (The Kesimpta PRIM study.) - post-authorisation study](https://catalogues.ema.europa.eu/study/50627)
- [Kesimpta (ofatumumab) pregnancy and infant safety study using real world data - post-authorisation study](https://catalogues.ema.europa.eu/study/106134)

**This page was last updated on** 16/12/2025

## Share this page

[Back to top](#main-content)